This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
The 18th World Conference on Lung Cancer (WCLC) will take place on 15–18 October 2017 at PACIFICO Yokohama Convention Center, Yokohama, Japan.
Boehringer Ingelheim will be presenting a symposium on treatment with afatinib* on 16 October 2016, 12:45–14:15. You can also visit us at booth 1300 to learn more about Boehringer Ingelheim’s collaborative approach to research and how we are already making the future brighter for people with cancer.
LUME-Meso Phase II/III Study: Nintedanib + pemetrexed/cisplatin in chemo-naïve patients with malignant pleural mesothelioma. (Presentation #7937)
Tsao et al.
Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME‑Meso Study. (Presentation #8111)
Nowak et al.
Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib. (Presentation #8797)
Hochmair et al.
Nintedanib/Docetaxel Efficacy in Advanced Lung Adenocarcinoma Treated with 1L Chemotherapy/2L Immunotherapy in Nintedanib NPU. (Presentation #8639)
Corral et al.
Sequential afatinib-osimertinib therapy in EGFR mutation-positive (EGFRm+) NSCLC: analysis of time on treatment and OS. (Presentation #9364)
Park et al.
Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC. (Presentation #9051)
Schuler et al.
A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis. (Presentation #9251)
Wu et al.
Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC. (Presentation #9365)
Hirsh et al.
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report). (Presentation #8250)
Yamamoto et al.
Impact of ErbB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SCC of the lung. (Presentation #9457)
Goss et al.
Phase Ib trial of xentuzumab and abemaciclib in advanced or metastatic solid tumors, including advanced NSCLC. (Presentation #8572)
Yee et al.
Afatinib in combination with pembrolizumab in patients with stage IIIB/IV squamous cell carcinoma of the lung. (Presentation #9425)
Riess et al.
How much do you know about Boehringer Ingelheim’s oncology pipeline and trials?
Take our quiz to find out.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.
¶Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue